We’re moving forward with the Phase 3 development program for our investigational once-daily triple combination regimen for people with cystic fibrosis.
Learn more
Vertex and CRISPR Therapeutics share new clinical data on investigational potential treatments for severe sickle cell disease and transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Annual Meeting
Read more about how we continued to operate as a responsible business, supported our communities and drove lasting social and environmental change in 2020.
A...Read more